Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04267380 · ClinicalTrials.gov registry record
A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A Day
A clinical trial of Arthritis, Rheumatoid, sponsored by Pfizer.
- Completed
- Registry status
- 298
- Enrollment target
- 1
- Study location
NCT04267380 is a study of Arthritis, Rheumatoid that has completed, run by Pfizer. The registered enrollment target is 298 participants, below the 630-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04267380, a study of Arthritis, Rheumatoid, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 298 participants
- Enrollment target
- 1
- Study location
Study Summary
It is hypothesized that patients prescribed tofacitinib 11 mg Modified Release (MR) formulation once daily (QD) will achieve similar benefit to those prescribed tofacitinib 5 mg twice a day (BID) dosage in real world use. This study will therefore seek to compare the effectiveness of the MR 11 mg QD regimen to the IR 5 mg BID regimen for the treatment of RA in a real-world registry of RA patients.
Conditions Studied
Study Locations (1)
New York
- Pfizer - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2018-09-30 |
| Est. Completion | 2019-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04267380
The ClinicalTrials.gov registry entry for NCT04267380 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 630-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (53% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 0 interventions.
NCT04267380 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04267380 about?
NCT04267380 is a clinical study titled "A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A Day". It is hypothesized that patients prescribed tofacitinib 11 mg Modified Release (MR) formulation once daily (QD) will achieve similar benefit to those prescribed tofacitinib 5 mg twice a day (BID) dosage in real world use. This study will therefore seek to compare the effectiveness of the MR 11 mg QD...
What is the current status of trial NCT04267380?
This trial is currently completed. The enrollment target is 298 participants. The study started on 2018-09-30. Estimated completion is 2019-08-31.
What conditions does trial NCT04267380 study?
This clinical trial studies the following conditions: Arthritis, Rheumatoid.
Who is sponsoring clinical trial NCT04267380?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04267380 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Rheumatoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chronic Pain in Rheumatoid Arthritis
RECRUITING
-
R-2487 in Patients With Rheumatoid Arthritis
RECRUITING · Phase 1
-
IMPACT - AndHealth Autoimmune Research Registry
RECRUITING
-
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
RECRUITING · Phase 2
-
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
RECRUITING
-
INFINITY™ With ADAPTIS™ Technology Study
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.